Dr Rupa Huq

Dr Rupa Huq

Labour — Ealing Central and Acton

Speaking in the House of Commons on 17 June 2025

Debate

Prostate Cancer Treatment

Contribution

I completely agree with the hon. Gentleman that access should be based not on how deep somebody’s pockets are, but on need. Abiraterone halves the risk of relapse. Each relapse literally costs the NHS millions—the definition of lose-lose. As many Members have pointed out, it is already successfully available on the NHS and routinely funded for use in metastatic cases in England, but sadly there is a catch: abiraterone is not available on the NHS for men with non-metastatic prostate cancer living in England.

More from Dr Rupa Huq

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

For Dr Rupa Huq's full parliamentary record including voting history, expenses and all other contributions, see the Dr Rupa Huq report card.